Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms (STARS)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02790034 |
Recruitment Status :
Terminated
(The study did not demonstrate evidence of efficacy on the primary or secondary efficacy variables)
First Posted : June 3, 2016
Results First Posted : December 21, 2021
Last Update Posted : December 21, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Rett Syndrome | Drug: Sarizotan low dose Drug: Sarizotan high dose Drug: Placebo | Phase 2 Phase 3 |
This is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and efficacy of multiple doses of sarizotan in patients with Rett syndrome with respiratory abnormalities. The study participants will be randomized to either sarizotan between 2 and 10 mg bid or placebo bid, based on age and weight criteria.
All patients who have completed the final evaluations at Week 24 (Day 168) and have no safety or tolerability issues that would preclude continuing on the study medication and have been compliant with the trial requirements will have the option of continuing open-label treatment with Sarizotan for up to 168 weeks.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 129 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms |
Actual Study Start Date : | October 26, 2016 |
Actual Primary Completion Date : | August 6, 2019 |
Actual Study Completion Date : | May 4, 2020 |
Arm | Intervention/treatment |
---|---|
Experimental: Sarizotan low dose
2 mg or 5 mg bid based on age and weight criteria for 24 wks DB 2 mg bid (4 to <13 years; ≥13 years of age and weighing <25 kg 5 mg bid (≥13 years of age and weighing ≥25 kg)
|
Drug: Sarizotan low dose
2 mg or 5 mg bid based on age and weight criteria for 24 wks DB 2 mg bid (4 to <13 years; ≥13 years of age and weighing <25 kg; 5 mg bid (≥13 years of age and weighing ≥25 kg). Assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients. |
Experimental: Sarizotan high dose
5 mg or 10 mg bid based on age and weight criteria for 24 wks DB 5 mg bid (4 to <13 years; ≥13 years of age and weighing <25 kg 10 mg bid (≥13 years of age and weighing ≥25 kg)
|
Drug: Sarizotan high dose
5 mg or 10 mg bid based on age and weight criteria for 24 wks DB 5 mg bid (4 to <13 years; ≥13 years of age and weighing <25 kg; 10 mg bid (≥13 years of age and weighing ≥25 kg) Assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients |
Placebo Comparator: Placebo
Placebo bid for 24 wks DB age 4 and above
|
Drug: Placebo
Placebo BID followed by assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients. |
- Reduction in Respiratory Abnormality in Patients With Rett Syndrome [ Time Frame: Baseline up to week 24 ]Measured as the percent change in the number of apnea episodes per hour during awake time, calculated using an ambulatory data acquisition system (BioRadioTM) as part of home monitoring procedure. BioRadioTM record specific respiratory and cardiac parameters.
- Efficacy of Sarizotan Assessed by the Caregiver-rated Impression of Change [ Time Frame: 24 weeks ]
Caregiver-rated Impression of Change (CIC): 7-point scale requiring the caregiver to rate how much the patient's illness has improved or worsened relative to the baseline state.
7-point Likert-type scale for which ratings range from 1 = very much improved to 7 = very much worse, with 4 = no change. This caregiver-rated measure considered activities, behavior, mood and functioning. This rating was performed in consultation with the study Investigator but was based largely on the caregivers' evaluation during the reporting period. The single rating of the CIC was to be based on changes in the following domains: • Activities (watching TV, interest in conversations around her, cooperation during toileting, dressing/bathing, etc.), • Communication (verbal or by eye movements, hand movements, or head movements), • Behavior (agitation, refusal to feed, scratching, social avoidance), • Participation in family/outdoor/social events)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 4 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Body weight ≥ 10 kg
- Age ≥ 4 years
- Diagnosis of Rett syndrome based on consensus clinical criteria and patients with MECP2 duplications will not be eligible.
- Has at least 10 episodes of breathing dysrhythmia, defined by episodes ≥10 seconds of breath holding (apnea), per hour during cardiorespiratory monitoring
- Ability to take study medication provided either as capsules or combined with food/drink.
- Patient is cooperative, willing to complete all aspects of the study, and capable of doing so with assistance of a caregiver.
Exclusion Criteria:
- Meets any of the diagnostic exclusion criteria for Rett syndrome, Typical (Neul et al, 2010);
- Patient is participating in a clinical trial with another investigational drug
- Hypersensitivity to sarizotan or other 5-HT1a agonists;
- Current clinically significant (as determined by Investigator) cardiovascular, respiratory (e.g. severe asthma), gastrointestinal, renal, hepatic, hematologic or other medical disorders, in addition to those directly related to the patient's Rett syndrome;
- QTcF interval on the ECG is greater than 450 msec.
- Surgery planned during the study (except for insertion of gastrostomy tube);
- Severe diabetes mellitus or fatty acid oxidation disorder.
- Ophthalmologic history including any of the following conditions: albino patients, family history of hereditary retinal disease, retinitis pigmentosa, any active retinopathy or severe diabetic retinopathy.
- Females who are pregnant, breastfeeding, or of childbearing potential and not using a hormonal contraceptive.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02790034
United States, Alabama | |
University of Alabama | |
Birmingham, Alabama, United States, 35233 | |
United States, California | |
University of California | |
San Diego, California, United States, 92093 | |
United States, Illinois | |
Rush University Medical Center | |
Chicago, Illinois, United States, 60612 | |
United States, Minnesota | |
Gillette Children's Specialty Healthcare | |
Saint Paul, Minnesota, United States, 55101 | |
United States, Texas | |
Baylor College of Medicine | |
Houston, Texas, United States, 77030 | |
Australia, Western Australia | |
South Metropolitan Health Service Fiona Stanley Hospital | |
Murdoch, Western Australia, Australia, 6961 | |
India | |
Amrita Institute of Medical Sciences | |
Kochi, Kerala, India, 682041 | |
Vijaya Health Centre | |
Chennai, Tamilnadu, India, 600 026 | |
P.D. Hinduja National Hospital and Medical Research Centre | |
Mumbai, India, 400 016 | |
Jaslok Hospital and Research centre | |
Mumbai, India, 400 026 | |
All India Institute of Medical Sciences | |
New Delhi, India, 110 029 | |
Italy | |
A.O.U. Senese Policlinico Santa Maria alle Scotte | |
Siena, Tuscany, Italy, 53100 | |
U.O. Neuropsichiatria Infantile | |
Milano, Italy, 20142 | |
United Kingdom | |
King's College Hospital | |
London, United Kingdom, SE5 8AF |
Study Director: | Ravi Anand, MD | Newron Pharmaceuticals |
Documents provided by Newron Pharmaceuticals SPA:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Newron Pharmaceuticals SPA |
ClinicalTrials.gov Identifier: | NCT02790034 |
Other Study ID Numbers: |
Sarizotan/001/II/2015 |
First Posted: | June 3, 2016 Key Record Dates |
Results First Posted: | December 21, 2021 |
Last Update Posted: | December 21, 2021 |
Last Verified: | November 2021 |
Rett Syndrome Syndrome Signs and Symptoms, Respiratory Disease Pathologic Processes Mental Retardation, X-Linked Intellectual Disability |
Neurobehavioral Manifestations Neurologic Manifestations Nervous System Diseases Genetic Diseases, X-Linked Genetic Diseases, Inborn Heredodegenerative Disorders, Nervous System |